Aricept to Improve Functional Tasks in Vascular Dementia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Medications for memory improvement are available but they may not actually improve the ability to do real world tasks. The purpose of this research study is to determine if a medicine used to treat memory problems donepezil(Aricept) enhances the ability to remember steps of functional tasks and the actual ability to perform tasks relevant to real-life independence. Aricept is an FDA approved medication for the treatment of Alzheimer's disease. Aricept is an investigational drug for the purposes of this study, and is not approved for this purpose.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neural Correlates In Mild Alzheimer's Disease

NCT00477659

Alzheimer's Disease

COMPLETED PHASE4

Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease

NCT00096473

Alzheimer's Disease Dementia

COMPLETED PHASE3

Donepezil to Treat Dementia in Parkinson's Disease

NCT00030979

Parkinson Disease

COMPLETED PHASE4

Treatment for Early Memory Loss

NCT00042172

Cognition Disorders Alzheimer Disease

COMPLETED PHASE4

A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI

NCT00483028

Alzheimer's Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All participants will receive a behavioral intervention as part of the testing protocol: they will be asked to generate words to complete a phrase as they read written steps to perform functional tasks. Mood will be assessed using the Geriatric Depression Scale.(see page 8) Participants will be asked to estimate their memory, immediate attention mood, functional tasks (performing cooking and financial task) and "ability to take medications correctly" (pre-test or "offline" ratings, abstract judgments of their own ability not based directly on performance). They will perform self-assessments of their cognitive, functional abilities and mood using Likert scales. They will mark each of 5 vertical (23.5 cm) lines centered on white paper to indicate their ability. Each line will be labeled for each domain.

To estimate of naming ability, show the subject the Likert Scale (attached) for the naming domain. Then explain: "This scale is to measure how well you think your ability to name. Here is the top where you will mark if you think your performance is perfect, here is the bottom if you think you are terrible. You may be somewhere in between. (broadly indicated the whole middle area) mark where you think your performance would belong on this scale".

This standard protocol will be used by the examiner in this study to explain each domain with specific types of tasks, and give subjects practical hypothetical examples of good and poor performance.

Ability to take medication: Functional memory as applied to medication compliance will be assessed with the Hopkins Medication Schedule (HMS). This test has two part, HMS and pill box. The test will serve as a good evaluation of subject's functional memory, which we suspect it will be most strongly affected by Anosognosia.

The HMS: the participant was read (and read along with) a hypothetical scenario in which her physician gave her 1 prescription for an antibiotic and for aspirin to treat an infection along with directions for taking each. The participant was then asked to plan a schedule for taking these medications and water during the course of a day, following the instructions provided.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Vascular Dementia Memory Deficits

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aricept- A

Half of subjects are randomized to immediate treatment with donepezil 5mg orally daily following baseline testing, with retesting at 12 and 24 weeks.

Group Type EXPERIMENTAL

Donepezil and self-generated memory training

Intervention Type DRUG

Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks

Donepezil and experimenter-administered memory training

Intervention Type DRUG

Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks

A2-12-week waiting period

The remaining nine subjects are randomized to testing followed by a 12-week waiting period. After the 12 week wait, this group of subjects is retested and begins taking donepezil, 5 mg orally daily, with retesting at 24 weeks

Group Type EXPERIMENTAL

Donepezil and self-generated memory training

Intervention Type DRUG

Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks

Donepezil and experimenter-administered memory training

Intervention Type DRUG

Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Donepezil and self-generated memory training

Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks

Intervention Type DRUG

Donepezil and experimenter-administered memory training

Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Aricept Aricept

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. I am 18 to100 yrs old.
2. I had one stroke 4 months to 5 yrs ago
3. I am not taking Aricept or other cholinesterase inhibitors (e.g. Exelon, Razadyne) or memantine (Namenda).

Exclusion Criteria

1. I have history of dementia and or have been diagnosed with a memory disorder prior to my stroke.
2. I have been on anti-depressants or other cognitive enhancing drugs for less than 3 months and the dose is not stabilized yet.
3. I consume alcohol more than or equivalent of 4 ounces hard liquor weekly.
4. I am taking oral anticholinergic medications like Bethanechol, Bentyl or Detrol.
5. I am a woman of childbearing potential or I am pregnant or a nursing mother.
6. I have a history of chronic vomiting or diarrhea.
7. I am allergic to Aricept.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No